drugset
drugset / Trial / NCT01666262

Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais

NCT01666262 ↗

Phase 1/2 Completed 363 enrolled Mahidol University
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate safety and reactogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) manufactured by GPO, Thailand, and to evaluate humoral immune response of the above vaccine after intranasal application by using HAI test, micro neutralization assays.

Timeline

Start
2009-09
Primary completion
—
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject A/17/CA/2009/38 (H1N1) Unknown — Intranasal

Indications

No indication recorded.